Profile: Ian Creese

Co-Director, Center for Molecular & Behavioral Neuroscience & Professor II

Faculty
Center for Molecular and Behavioral Neuroscience

 

Paving the Way for a Deeper Understanding of the Brain

A noted pharmacologist, Ian Creese during the course of his research career has shed new light on the effect of antipsychotic drugs on the inner workings of the brain, specifically looking at such disorders as schizophrenia and Parkinson's. Further paving the way for a deeper understanding of the brain, Creese as co-founder and co-director of the Center for Molecular and Behavioral Neuroscience (CMBN) has paved the way for other researchers and students to unlock the secrets of brain development and neurological disorders. Creese, working with co-director and co-founder Paula Tallal, has established CMBN since its founding in 1985 as an internationally recognized neuroscience research center focused on a wide-range of brain functions and disorders, from brain development in children, to memory formation, to Alzheimer's, dyslexia and Parkinson's disease. Creese also is co-director of the Integrative Neuroscience Graduate Program at the University of Medicine and Dentistry of New Jersey. As a researcher, Creese is a world-renowned expert in the field of dopamine receptors and the role antipsychotic drugs play in receptor changes. Among his major findings, his research has shown that while antipsychotic drug treatment has focused on regulating dopamine receptors, regulating serotonin and glutamate receptors also may be important to increase the efficacy of drug therapies for such disorders as schizophrenia and Parkinson's.

  • Courses Taught

     

    Foundations of Neuroscience I

    Foundations of Neuroscience II

  • Education

     

    Ian Creese studied psychology at the University of Cambridge, where he earned his bachelor's, master's and doctoral degrees in experimental psychology. He served as a postdoctoral fellow at the Johns Hopkins University Medical School in Baltimore. He joined the faculty of the University of California at San Diego, School of Medicine, in 1978, before coming to Rutgers University, Newark in 1987 to co-found the Aidekman Center for Molecular and Behavioral Neuroscience with Paula Tallal. Creese has published nearly 150 research articles, scores of invited chapters and has edited four books. His research is so widely recognized that he was listed as a "Citation Superstar" by the Science Citation Index with more 5,000 citations to his research. For his accomplishments, Creese was named a Rutgers Board of Governors Professor of Neuroscience in 2001, the university's highest academic honor.

  • Publications

     

    Thesis

    Creese, I., Drug induced motor stimulation: a psychopharmacological investigation. 208pp., University of Cambridge.

     

    Reviewed Articles

    1. Creese, I., and Iversen, S.D., Amphetamine response in rat after dopamine neurone destruction. Nature New Biology 238: 247-248, 1972.

    2. Creese, I. and Iversen, S.D., Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Brain Research 55: 369-382, 1973.

    3. Creese, I. Behavioral evidence of dopamine receptor stimulation by piribedil (ET495) and its metabolite S584. European Journal of Pharmacology 28: 55-58, l974.

    4. Creese, I. and Iversen, S.D., The role of forebrain dopamine systems in amphetamine induced stereotyped behavior in the rat. Psychopharmacologia, 39: 345-357, 1974.

    5. *Creese, I. and Iversen, S.D., The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Research, 83: 419-436, 1975.
    *Included in the top 53 most highly cited Life Sciences Articles in 1975, Current Contents, April 2, 1976.

    6. Creese, I. and Snyder, S.H., Receptor binding and pharmacological activity of opiates in the guinea pig intestine. Journal of Pharmacology and Experimental Therapeutics 194: 205-219, 1975.

    7. Creese, I, Pasternak, G., Pert, C. and Snyder, S.H., Discrimination by temperature of opiate agonist and antagonist receptor binding. Life Sciences, 16: 1837-1842, 1975.

    8. Creese, I., Burt, D.R. and Snyder, S.H., Dopamine receptor binding: differentiation of agonist-antagonist states with 3H-dopamine and 3H-haloperidol. Life Sciences, 17: 993-1002, 1975.

    9. Creese, I., Burt, D.R. and Snyder, S.H., The dopamine receptor: differential binding of LSD and related agents to agonist and antagonist states. Life Sciences, 17: 1715-1720, 1975.

    10. Burt, D.R., Enna, S.J., Creese,I. and Snyder, S.H., Dopamine receptor binding in corpus striatum of mammalian brain. Proceedings of the National Academy of Sciences, U.S.A., 72: 4655-4699, 1975.

    11. Snyder, S.H., Creese, I. and Burt, D.R., The brain's dopamine receptor: labeling with 3H-dopamine and 3H-haloperidol. Psychopharmacology Communications 1: 663-673, 1975.

    12. Creese, I., Feinberg, A. and Snyder, S.H., Butyrophenone influences on the opiate receptor. European Journal of Pharmacology 36: 231-235, 1976.

    13. **Creese, I., Burt, D.R. and Snyder, S.H., Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481-483, 1976.
    **Included in the top 100 most highly cited Life Sciences Articles in 1976, Current Contents, March 26,1979 and selected as a Citation Classic, Current Contents, 1988.

    14. Burt, D.R., Creese, I. and Snyder, S.H., Binding interactions of LSD and related agents with dopamine receptors in the brain. Molecular Pharmacology, 12: 631-638, 1976.

    15. Burt, D.R., Creese, I. and Snyder, S.H., Properties of 3H-haloperidol and 3H-dopamine binding associated with dopamine receptors in calf brain. Molecular Pharmacology, 12: 800-812, 1976.

    16. Enna, S.J., Bennett, J.P., Jr., Burt, D.R., Creese, I. and Snyder, S.H., Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency. Nature 263: 338-341, 1976.

    17. Creese, I. Burt, D.R. and Snyder, S.H., Dopamine receptors and average clinical doses. Science, 194: 546, 1976.

    18. Feinberg, A.P., Creese, I. and Snyder, S.H., The opiate receptor: a model explaining structure-activity relationships of opiate agonists and antagonists, Proceedings of the National Academy of Sciences, U.S.A., 73: 4215-4219, 1976.

    19. Enna, S.J., Bennett, J.P., Jr., Bylund, D.B., Creese, I., Burt, D.R., Charness, M.T., Yamamura, H.I., Simantov, R. and Snyder, S.H., Neurotransmitter receptor binding: regional distribution in human brain. Journal of Neurochemistry, 28: 233-236, 1977.

    20. ***Burt, D.R., Creese, I. and Snyder, S.H., Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding. Science, 196: 326-328, 1977.
    ***Included in the top 100 most highly cited Life Sciences Articles in 1977-1979, Current Contents, July 21, 1980.

    21. Pardo, J.V., Creese, I., Burt, D.R. and Snyder, S.H., Ontogenesis of dopamine receptor binding in the corpus striatum of rat. Brain Research, 125: 376-382, 1977.

    22. Enna, S.J., Bennett, J.P., Burt, D.R., Creese, I., U'Prichard, D.C., Greenberg, D.A. and Snyder, S.H., Stereospecificity and clinical potency of neuroleptics, reply. Nature, 267: 184, 1977.

    23. Creese, I., Burt, D.R. and Snyder, S.H., Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science, 197: 596-598, 1977.

    24. Creese, I. and Snyder, S.H., A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature, 270: 180-182, 1977.

    25. Creese, I., Schneider, R. and Snyder, S.H., 3H-Spiroperidol labels dopamine receptors in pituitary and brain. European Journal of Pharmacology, 46: 377-381, 1977.

    26. ****Schwarcz, R., Creese, I., Coyle, J.T. and Snyder, S.H., Dopamine receptors localized on cerebral cortical afferents to rat corpus striatum. Nature, 271: 766- 768, 1978.
    ****Included in the highly cited Life Sciences Articles in 1978 and 1979, Current Contents, November 24, 1980.

    27. Creese, I., Manian, A.A., Prosser, T.D. and Snyder, S.H., 3H-Haloperidol binding to dopamine receptors in rat corpus striatum: influence of chlorpromazine metabolites and derivatives. European Journal of Pharmacology, 47: 291-297, 1978.

    28. Thal, L., Creese, I. and Snyder, S.H., 3H-Apomorphine interactions with dopamine receptors in calf brain. European Journal of Pharmacology, 49: 295-299, 1978.

    29. Creese, I. and Snyder, S.H., 3H-Spiroperidol labels serotonin receptors in rat cerebral cortex and hippocampus. European Journal of Pharmacology, 49: 201-202, 1978.

    30. Creese, I., Prosser, T. and Snyder, S.H., Dopamine receptor binding: specificity, localization and regulation by ions and guanyl nucleotides. Life Sciences, 23: 495-500, 1978.

    31. Creese, I. and Snyder, S.H., Dopamine receptor binding of 3H-ADTN regulated by guanyl nucleotides. European Journal of Pharmacology, 50: 459-461, 1978.

    32. Childers, S.R., Creese, I., Snowman, A.M. and Snyder, S.H., Opiate receptor binding affected differentially by opiates and opioid peptides. European Journal of Pharmacology, 55: 1-18, 1979.

    33. Creese, I., Usdin, T. and Snyder, S.H., Guanine nucleotides distinguish two dopamine receptors. Nature, 278: 577-578, 1979.

    34. Freedberg, K.A., Innis, R.B., Creese, I., and Snyder, S.H., Antischizophrenic drugs: differential plasma protein binding and therapeutic activity. Life Sciences, 24: 2467-2474, 1979.

    35. Sibley, D.R. and Creese, I., Guanine nucleotides regulate anterior pituitary dopamine receptors. European Journal of Pharmacology, 55: 341-343, 1979.

    36. Creese, I., Usdin, T. and Snyder, S.H., Dopamine receptor binding regulated by guanine nucleotides. Molecular Pharmacology, 16: 69-76, 1979.

    37. Creese, I. and Snyder, S.H., Nigrostriatal lesions enhance striatal 3H-apomorphine and 3H-spiroperidol binding. European Journal of Pharmacology, 56: 277-281, 1979.

    38. Creese, I., Padgett, L., Fazzini, E. and Lopez, F., 3H-N-Propylnorapomorphine: A novel agonist ligand for central dopamine receptors. European Journal of Pharmacology, 56: 411-412, 1979.

    39. Creese, I., Stewart, K. and Snyder, S.H., Species variations in dopamine receptor binding. European Journal of Pharmacology, 60: 55-66, 1979.

    40. Calil, H.M., Avery, D.H., Hollister, L.E., Creese, I. and Snyder, S.H., Serum levels of neuroleptics measured by dopamine radioreceptor assay and some clinical observations. Psychiatry Research, 1: 39-44, 1979.

    41. Creese, I. and Sibley, D.R., Radioligand binding studies: evidence for multiple dopamine receptors. Communications in Psychopharmacology, 3: 385-395, 1979.

    42. Tune, L.E., Creese, I., DiPaulo, J.R., Slavney, P.R. and Snyder, S.H., Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia. American Journal of Psychiatry, 137: 187-190, 1980.

    43. Usdin, T.B., Creese, I. and Snyder, S.H., Regulation by cations of 3H-spiroperidol binding associated with dopamine receptors of rat brain. Journal of Neurochemistry, 34: 669-676, 1980.

    44. Tune, L.E., Creese, I., Coyle, J.T., Pearlson, G. and Snyder, S.H., Low neuroleptic serum levels in patients receiving fluphenazine decanoate. American Journal of Psychiatry, 137: 80-82, 1980.

    45. Sibley, D.R. and Creese, I., Dopamine receptor binding in bovine intermediate pituitary membranes. Endocrinology, 107: 1405-1409, 1980.

    46. Burnett, G.B., Prange, Jr., A.J., Wilson, I.C., Jolliff, L.A., Creese, I. and Snyder, S.H., Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. An investigation of mechanism. Neuropsychobiology, 6: 109-120, 1980.

    47. Sibley, D.R. and Creese, I., Pseudo non-competitive agonist interactions with dopamine receptors. European Journal of Pharmacology, 65: 131-133, 1980.

    48. Hamblin, M. and Creese, I., Phenoxybenzamine discriminates multiple dopamine receptors. European Journal of Pharmacology, 65: 119-121, 1980.

    49. Mackay, A.V.P., Bird, E.D., Spokes, E.G., Rossor, M., Creese, I., Snyder, S.H. and Iversen, L.L., Dopamine receptors and schizophrenia: drug effect or illness? Lancet ii: 915-916, 1980.

    50. Tune, L.E., Creese, I., DiPaulo, J.R., Slavney, P.R., and Snyder, S.H., Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenic patients. Journal of Nervous and Mental Diseases, 169: 60-63, 1981.

    51. Creese, I., Sibley, D.R., Hamblin, M., and Leff, S. E., Dopamine receptors: subtypes, regulation, and localization. Federation Proceedings, 40: 147-152, 1981.

    52. Leff, S., Adams, L., Hyttel, J. and Creese, I., Kainate lesion dissociates striatal dopamine receptor radioligand binding sites. European Journal of Pharmacology, 70: 71-75, 1981.

    53. Creese, I. and Sibley, D.R., Receptor adaptations to centrally acting drugs. Annual Review of Pharmacology and Toxicology, 21: 357-391, 1981.

    54. Leff, S., Sibley, D.R., Hamblin, M. and Creese, I., Ascorbic acid enables reversible dopamine receptor 3H-agonist binding. Life Sciences, 29: 2081-2090, 1981.

    55. Hamblin, M. and Creese, I., Receptor binding and the discovery of psychotherapeutic drugs. Drug Research, 1: 343-372, 1981.

    56. Meltzer, H.Y., Busch, D.A., Creese, I., Snyder, S.H. and Fang, V.S., Effect of intramuscular chlorpromazine on serum prolactin levels in schizophrenic patients and normal controls: correlation with levels of chlorpromazine equivalents. Psychiatry Research, 5: 95-105, 1981.

    57. Sanberg, P.R. and Creese, I., Dopamine receptor stimulation and striatal kainic acid neurotoxicity. Journal of Pharmacy and Pharmacology, 33: 674-675, 1981.

    58. Creese, I., Dopamine receptors explained. Trends in Neuroscience, 5: 40-43, 1982.

    59. Hamblin, M.W. and Creese, I., Phenoxybenzamine treatment differentiates dopaminergic 3H-ligand binding sites in bovine caudate membranes. Molecular Pharmacology, 21: 41-51, 1982.

    60. Hamblin, M.W. and Creese, I., Heat treatment mimics guanosine-5'-triphosphate effects on dopaminergic 3H-ligand binding to bovine caudate membranes. Molecular Pharmacology, 21: 52-56, 1982.

    61. Hamblin, M.W. and Creese, I., 3H-Dopamine binding to rat striatal D2 and D3 sites: enhancement by magnesium and inhibition by sodium. Life Sciences, 30: 1587-1595, 1982.

    62. Sibley, D.R., De Lean, A. and Creese, I., Anterior pituitary dopamine receptors: demonstration of interconvertible high and low affinity states of the D2 dopamine receptor. Journal of Biological Chemistry, 257: 6351-6361, 1982.

    63. Sibley, D.R., Leff, S.E. and Creese, I., Interactions of novel dopaminergic ligands with D1 and D2 dopamine receptors. Life Sciences, 31: 637-645, 1982.

    64. Chouinard, G., Creese, I., Boisvert, D., Annable, L., Bradweijn, J. and Jones, B., High neuroleptic plasma levels in patients manifesting supersensitivity psychosis. Biological Psychiatry, 17: 849-852, 1982.

    65. Creese, I., Kuczenski, R. and Segal, D., Lack of behavioral evidence for dopamine autoreceptor subsensitivity after acute electroconvulsive shock. Pharmacology, Biochemistry and Behavior, 17: 375-376, 1982.

    66. Leff, S.E. and Creese, I., Solubilization of D2 dopamine receptors from canine caudate: agonist-occupation stabilizes guanine nucleotide sensitive receptor complexes. Biochemical and Biophysical Research Communications, 108: 1150-1157, 1982.

    67. Creese, I. and Leff, S.E., Dopamine receptors: A classification. Journal of Clinical Psychopharmacology, 2: 329-335, 1982.

    68. Mackay, A.V.P., Iversen, L.L., Rossor, M., Spokes, E., Bird, E., Arregui, A., Creese, I. and Snyder, S.H., Increased brain dopamine and dopamine receptors in schizophrenia. Archives of General Psychiatry, 39: 991-997, 1982.

    69. Sibley, D.R., Weinberger, S., Segal, D.S. and Creese, I., Multiple daily amphetamine administration decreases both 3H-agonist and 3H-antagonist dopamine receptor binding. Experimentia, 38: 1224, 1982.

    70. Creese, I. and Sibley, D.R., Comment on a commentary. Biochemical Pharmacology, 31: 2568-2569, 1982.

    71. Creese, I., Sibley, D.R., Hamblin, M.W. and Leff, S.E., The classification of dopamine receptors: relationship to radioligand binding. Annual Review of Neuroscience, 6: 43-71, 1983.

    72. Sibley, D.R., Mahan, L.C. and Creese, I., Dopamine receptor binding on intact cells: absence of a high affinity agonist-receptor binding state. Molecular Pharmacology, 23: 295-302, 1983.

    73. Sibley, D.R. and Creese, I., Interactions of ergot alkaloids with anterior pituitary D2 dopamine receptors. Molecular Pharmacology, 23: 585-593, 1983.

    74. Hamblin, M.W. and Creese, I., Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Life Sciences, 32: 2247-2255, 1983.

    75. Sibley, D.R. and Creese, I., Regulation of ligand binding to pituitary D2 dopaminergic receptors: effects of divalent cations and functional group modification. Journal of Biological Chemistry, 258: 4957-4965, 1983.

    76. Creese, I., Die dopamine-rezeptoren. Nervenheilkunde-Zeitschrift Interdisziplinare, 2: 88-93, 1983.

    77. Leff, S.E. and Creese, I., Dopamine receptors re-explained. Trends in Pharmacological Sciences, 4: 463-467, 1983.

    78. Morrow, A.L., Loy, R. and Creese, I., Cholinergic denervation induces adrenergic receptor increases: correlation with sympathetic axon sprouting in hippocampus. Proceedings of the National Academy of Sciences, U.S.A., 80: 6718-6722, 1983.

    79. Leff, S.E. and Creese, I., Dopaminergic D3 binding sites are postsynaptic. Nature, 306: 586-589, 1983.

    80. Creese, I., Classical and atypical antipsychotic drugs: new insights. Trends in Neuroscience 6: 479-481, 1983.

    81. Hamblin, M.W., Leff, S.E. and Creese, I., Interactions of agonists with D2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranes. Biochemical Pharmacology, 33: 877-887, 1984.

    82. Creese, I., Sibley, D.R. and Leff, S.E., Agonist interactions with dopamine receptors: focus on radioligand binding studies. Federation Proceedings, 43: 2779-2784, 1984.

    83. Leff, S.E., Chen, A. and Creese, I., Sulpiride isomers exhibit reversed stereospecificity for D1 and D2 dopamine receptors in the CNS. Neuropharmacology, 23: 589-590, 1984.

    84. Norman, A.B., Battaglia, G., Morrow, A.L. and Creese, I., [3H]WB-4101 labels S1 serotonin receptors in rat cerebral cortex. European Journal of Pharmacology, 106: 461-462, 1984.

    85. Leff, S.E., Gariano, R. and Creese, I., Dopamine receptor turnover rates in rat striatum are age-dependent. Proceedings of the National Academy of Sciences, U.S.A., 81: 3910-3914, 1984.

    86. Leff, S.E., Hamblin, M.W. and Creese, I., Interactions of dopamine agonists with brain D1 receptors labeled by 3H-antagonists: Evidence for the presence of high and low affinity agonist-binding states. Molecular Pharmacology, 27: 171-183, 1985.

    87. Leff, S.E. and Creese, I., Interactions of dopaminergic agonists and antagonists with dopaminergic "D3" binding sites in rat striatum: Evidence that [3H]dopamine can label a high-affinity agonist binding state of the D1 dopamine receptor. Molecular Pharmacology, 27: 184-192, 1985.

    88. Morrow, A.L., Loy, R. and Creese, I., Alteration of nicotinic agonist binding sites in hippocampus after fimbria transection. Brain Research, 344: 309-314, 1985.

    89. Morrow, A.L., Battaglia, G., Norman, A.N. and Creese, I., Identification of subtypes of [3H]prazosin-labeled alpha-1 receptor binding sites in rat brain. European Journal of Pharmacology, 109: 285-287, 1985

    90. Creese, I., and Chen, A., Selective D1 dopamine receptor increase following chronic treatment with SCH23390. European Journal of Pharmacology, 109: 127-128, 1985.

    91. Battaglia, G., Norman, A.B., Hess, E.J. and Creese, I., D2 dopamine receptor-mediated inhibition of forskolin stimulated adenylate cyclase activity in rat striatum. Neuroscience Letters, 59: 177-182, 1985

    92. Morrow, A.L., Norman, A.B., Battaglia, G., Loy, R. and Creese, I., Up-regulation of serotonergic binding sites labeled by [3H]WB4101 following fimbrial transection and 5,7-dihydroxytryptamine-induced lesions. Life Sciences, 37: 1913-1922, 1985.

    93. Norman, A.B., Battaglia, G. and Creese, I., [3H]WB4101 labels the 5-HT1A serotonin receptor subtype in rat brain: Guanine nucleotide and divalent cation sensitivity. Molecular Pharmacology 28: 487-494, 1985.

    94. Hess, E.J., Battaglia, G., Norman, A.B., Iorio, L.C. and Creese, I., Guanine nucleotide regulation of agonist interactions at [3H]SCH23390 labeled D1 dopamine receptors in rat striatum. European Journal of Pharmacology, 121: 31-38, 1986.

    95. Morrow, A.L., Chen, A.D. and Creese, I., Modulation of alpha-1 adrenergic receptors in rat brain following chronic reserpine. Neurochemistry International, 8: 243-247, 1986.

    96. Battaglia, G., Norman, A.B., Newton, P.L. and Creese, I., In vitro and in vivo irreversible blockade of cortical S2 serotonin receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): A technique for investigating S2 serotonin receptor recovery. Journal of Neurochemistry, 46: 589-593, 1986.

    97. Battaglia, G., Norman, A.B., Hess, E.J. and Creese, I., Forskolin potentiates the stimulation of rat striatal adenylate cyclase mediated by D1 dopamine receptors guanine nucleotides and sodium fluoride. Journal of Neurochemistry, 46: 1180-1185, 1986.

    98. Morrow, A.L. and Creese, I., Characterization of alpha-1 adrenergic receptor subtypes in rat brain: A reevaluation of [3H]WB4101 and [3H]prazosin binding. Molecular Pharmacology, 29: 321-330, 1986.

    99. Norman, A.B., Battaglia, G. and Creese, I., Regulation of putative muscarinic cholinergic receptor subtypes in rat brain. Neurochemistry International, 9: 337-347, 1986.

    100. Hess, E.J., Albers, L.J., Le, H. and Creese, I., The effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: Potentiated behavioral responses to a D2 dopamine agonist following selective D1 dopamine receptor up-regulation. Journal of Pharmacology and Experimental Therapeutics, 238: 846-854, 1986.

    101. Amalric, M., Koob, G.F., Creese, I. and Swerdlow, N.R. "Selective" D1 and D2 receptor antagonists fail to differentially alter "supersensitive" locomotor behavior in the rat. Life Sciences, 39: 1985-1993, 1986.

    102. Battaglia, G., Norman, A.B., Hess, E.J. and Creese, I., Functional recovery of D1 dopamine receptor-mediated stimulation of rat striatal adenylate cyclase activity following irreversible receptor modification by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): Evidence for spare receptors. Neuroscience Letters, 69: 290-295, 1986.

    103. Norman, A.B., Blaker, S.N., Thal, L. and Creese, I., Effects of aging and cholinergic deafferentation on putative muscarinic cholinergic receptor subtypes in rat cerebral cortex. Neuroscience Letters, 70: 289-294, 1986.

    104. Norman, A.B. and Creese, I. , Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on putative muscarinic receptor subtypes in rat brain. Molecular Pharmacology, 30: 96-103, 1986.

    105. Hess, E.J. and Creese, I., Biochemical and behavioral studies of D1 dopamine receptors utilizing SCH23390. Psychopharmacology 22: 605-612, 1986.

    106. Creese, I. and Hess, E.J., Biochemical characteristics of D1 dopamine receptors: Relationship to behavior and schizophrenia. Clinical Neuropharmacology, 9: 14-19, 1986.

    107. Hess, E.J., Battaglia, G. Norman, A.B. and Creese, I., Differential modification of striatal D1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) in vivo and in vitro. Molecular Pharmacology, 31: 50-57, 1987.

    108. Norman, A.B., Battaglia, G. and Creese. I. , Differential recovery rates of rat D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: A key to receptor regulatory mechanisms. Journal of Neuroscience, 7: 1484-1491, 1987.

    109. Hess, E.J., Bracha, S., Kleinman, J.E. and Creese, I., Dopamine receptor subtype imbalance in schizophrenia. Life Sciences, 40: 1487-1497, 1987.

    110. Battaglia, G., Norman, A.B. and Creese, I., Differential serotonin receptor recovery in mature and senescent rat brain following irreversible receptor modification: Effect of chronic reserpine treatment. Journal of Pharmacology & Experimental Therapeutics, 243: 69-75, 1987.

    111. Koob, G.F., Le, H.T., Creese, I., The D1 dopamine receptor antagonist SCH23390 increases cocaine self-administration in the rat. Neuroscience Letters, 79:315-320, 1987.

    112. Battaglia, G., Norman, A.B. and Creese, I. Age-related differential recovery rates of rat striatal D1 dopamine receptors following irreversible receptor inactivation. European Journal of Pharmacology, 145: 281-290, 1988.

    113. Hess, E.J., Norman, A.B. and Creese, I., Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors. Journal of Neuroscience, 8:2361-2370, 1988.

    114. Friedhoff, A.J., Pickar, D., Axelrod, J., Creese, I., Davis, K.L., Gallagher, D.W., Greengard, P., Housman, D., Maas, J.W., Richelson, E., Roth and R. H., Watson, S.J. and Neurochemistry and Neuropharma-cology. Schizophrenia Bulletin (National Institute of Mental Health) 14:399-412, 1988.

    115. Norman, A.B., Eubanks, J.H. and Creese, I. Irreversible and quaternary muscarinic antagonists discriminate multiple muscarinic receptor binding sites in rat brain. Journal of Pharmacology & Experimental Therapeutics, 248:1116-1122, 1989.

    116. Riva, M. and Creese, I. Re-Evaluation of the regulation of b-adrenergic receptor binding by desipramine treatment. Molecular Pharmacology, 36:211-218, 1989.

    117. Riva, M. and Creese, I. Comparison of two putatively selective radioligands for labelling CNS b-adrenergic receptors: Inadequacy of [3H]dihydroalprenolol. Molecular Pharmacology, 36:201-210, 1989.

    118. Van Tol, H.M., Riva, M., Civelli, O. and Creese, I. Lack of effect of chronic dopamine receptor blockade on D2 dopamine receptor mRNA levels. Neuroscience Letters, 111:303-308, 1990.

    119. Riva, M. and Creese, I. Effect of chronic administration of dopamine receptor antagonists on D1 and D2 dopamine receptors and s-haloperidol binding sites in rat brain. Molecular Neuropharmacology, 1:17-22, 1990.

    120. Kirch, D.G., Taylor, T.R., Creese, I., Xu, S.-X., Wyatt, R.J. Effect of chronic nicotine treatment and withdrawal on rat striatal D1 and D2 dopamine receptors. Journal of Pharmacy and Pharmacology, 42:89-92, 1991.

    121. Xu, S., Hatada, Y., Black, L.E., Creese, I. and Sibley, D.R. N-(pisothiocyanato-phenethyl) spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain. Journal of Pharmacology and Experimental Therapeutics, 257:608-615, 1991.

    122. Tepper, J.M., Creese, I., and Schwartz, D.H. Factors controlling the stimulated overflow of neostriatal dopamine in awake and anesthetized rats. Brain Research, 559:283-292, 1991.

    123. Jinnah, H.A., Norman, A.B. and Creese, I. The effects of ions, guanine nucleotides, and N-ethylmaleimide on the proportions of pirenzepine-defined M1 and M2 muscarinic acetylcholine receptors in rat brain. Life Science Advances - Neurochemistry, 10:29-41, 1991.

    124. Creese. I., Sibley, D.R. and Xu, S.X. Expression of rat striatal D1 and D2 dopamine receptor mRNAs: Ontogenetic and pharmacological studies. Neurochemistry International 20, Suppl. 45-48, 1992.

    125. Xu, S., Monsma, Jr., F.J., Sibley, D.R. and Creese, I. Regulation of D1 and D2 dopamine receptor mRNA during ontogenesis and chronic antagonist treatment. Life Sciences, 50:383-396, 1992.

    126. Zhang, M. and Creese, I. Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates. Neuroscience Letters, 161:223-226, 1993.

    127. Zang, Z., Florijn, W. and Creese, I., Reduction in muscarinic receptors by antisense oligodeoxy-nucleotide. Biochemical Pharmacology, 48:225-228, 1994.

    128. Koutouzis, T.K., Borlongan, C.V., Scorcia, T., Creese, I., Cahill, D.W., Freeman, T.B. and Sanberg, P.R., Systemic 3-nitropropionic acid: long-term effects on locomotor behavior. Brain Research, 646:242-246, 1994.

    129. Pothos, E.N., Creese, I., Auerbach, S.B. and Hoebel, B.G., Restricted eating with weight loss selectively decreases extracellular dopamine in the nucleus accumbens and alters dopamine response to amphetamine, morphine, and food intake. Journal of Neuroscience, 15:6640-6650, 1995.

    130. Tarazi, F.I., Florijn, W.J. and Creese, I., Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology, 128:371-379, 1996.

    131. Dong, Z.J., Chen, L.J., Jin, G.Z. and Creese, I., GTP regulation of (-) stepholidine binding to RH of D1 dopamine receptors in calf striatum. Biochemical Pharmacology, (in press) 1997.

    132. Tepper, J. M., Sun, B.-C., Martin, L. P. and Creese, I. , Functional roles of dopamine D2 and D3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown in vivo. Journal of Neuroscience, (in press) 1997.

    133. Tarazi, F.I., Florijn, W.J. and Creese, I., Differential regulation of dopamine receptors following chronic typical and atypical antipsychotic drug treatment. Neuroscience, (in press) 1997.

    134. Florijn, W.J., Tarazi , F.I. and Creese, I., Dopamine receptor subtypes: differential regulation following 8 months treatment with antipsychotic drugs. Journal of Pharmacology and Experimental Therapeutics, 280:561-569, 1997.

    135. Zang, Z. and Creese, I., Differential regulation of expression of rat hippocampal muscarinic receptor subtypes following fimbria-fornix lesion. Biochemical Pharmacology , 53:1997.

    136. Lee, H., Tarazi, F.I., Chakos, M., Wu, H., Redmond, M., Alvir, J.M., Kinon, B.J., Bilder, R., Creese, I. and Lieberman, J.A., Effects of chronic treatment with typical and atypical antipsychotic drugs on the caudate nucleus in the rat. Psychopharmacology (submitted) 1997.

    137. Creese, I., Rate processing constraints may underlie developmental language impairments and also hemispheric specialization for speech. Brain Research Bulletin 50:431-432, 1999.

    138. Ouagazzal, A.-M. and Creese, I., Intra-accumbens infusion of D3 receptor agonists reduces spontaneous and dopamine-induced locomotion. Pharmacology, Biochemistry and Behavior 67:637-645, 2000.

     

     

    Books

    1. Snyder, S.H. and Matthysse, S. with Akil, H., Creese, I., Mansky, P. and Pasternak, G. (eds.), Opiate Receptor Mechanisms,, 166 pp, M.I.T. Press, Cambridge, 1975.

    2. Creese, I. (ed.), Stimulants: Neurochemical, Behavioral and Clinical Perspectives, Raven Press, N.Y., 350 pp., 1983.

    3. Breese, G.R. and Creese, I. (eds.), Neurobiology of Central D1 Dopamine Receptors, Plenum Press, NY., 219 pp., 1986.

    4. Creese, I. and Fraser, C. (eds.), Dopamine Receptors, A.R. Liss, NY., 261 pp., 1987.

     

     

    Invited Chapters

    1. Iversen, S.D. and Creese, I., Behavioral correlates of dopaminergic supersensitivity. In Advances in Neurology, Vol. 9, (eds.) D. Calne, T.N. Chase and A. Barbeau, Raven Press, New York, pp. 81-92, 1974.

    2. Creese, I. and Iversen, S.D., Behavioral sequelae of dopaminergic degeneration: postsynaptic supersensitivity? Psychopharmacology Bulletin, 11: 12-13, 1975.

    3. Snyder, S.H. and Matthysse, S. with Akil, H., Creese, I., Mansky, P. and Pasternak, G., (eds.), Opiate receptor mechanisms. Neuroscience Research Program Bulletin, 3, 1975.

    4. Creese, I. and Iversen, S.D., Behavioral sequelae of dopaminergic degeneration: postsynaptic supersensitivity? In Pre- and Postsynaptic Receptors, (eds.) E. Usdin and W.E. Bunney, Marcel Dekker, New York, pp. 171-190, 1975.

    5. Creese, I. and Snyder, S.H., Relationship between receptor binding and pharmacological activity of opiates in the guinea pig intestine. Proceedings of the 37th Annual Meeting of the Committee on Drug Dependence, National Academy of Science, U.S.A., Washington, D.C., pp. 796-812, 1975.

    6. Creese, I., Pasternak, G., Pert, C. and Snyder, S.H., Discrimination by temperature of opiate agonist and antagonist receptor binding. In The Opiate Narcotics: Neurochemical Mechanisms in Analgesia and Dependence, (ed.) A. Goldstein, Pergamon Press, New York, pp. 85- 90, 1975.

    7. Snyder, S.H., Burt, D.R. and Creese, I., The dopamine receptor of mammalian brain: direct demonstration of binding to agonist and antagonist states. Neuroscience Symposia, 1: 28-49, 1976.

    8. Creese, I. and Snyder, S.H., The opiate receptor: relevance of binding to pharmacological activity. In Tissue Responses to Addictive Drugs, (eds.) D. Clouet and D. Ford, Spectrum Press, New York, pp. 315-334, 1976.

    9. Snyder, S.H., Creese, I.. and Burt, D.R., Dopamine receptor binding to mammalian brain: relevance to psychiatry. In Neuroregulators and Psychiatric Disorders, (eds.) E. Usdin, D. Hamburger and J. Barchas, Oxford University Press, New York, pp. 526-537, 1977.

    10. Creese, I. and Snyder, S.H., Brain neurotransmitter receptor binding and neuroleptic drugs. Annual Reports in Medical Chemistry, 12: 249-259, 1977.

    11. Creese, I. and Snyder, S.H., Brain neurotransmitter and drug receptors. In Medicinal Chemistry V, (ed.) J. Mathieu, Elsevier Scientific Company, Amsterdam and New York, pp. 135-153, 1977.

    12. Creese, I. and Snyder, S.H., Behavioral and biochemical properties of the dopamine receptors. In Psychopharmacology: A Generation of Progress, (eds.) M.A. Lipton, A. DiMascio and K.F. Killam, Raven Press, New York, pp. 377-388, 1978.

    13. Creese, I. and Snyder, S.H., Biochemical identification of neurotransmitter receptors in the brain. In Neuronal Information Transfer, (eds.) A. Karlin, V.M. Tennyson and H.J. Vogel, Academic Press, New York, pp. 73-94, 1978.

    14. Creese, I. and Snyder, S.H., Biochemical hypotheses of schizophrenia. In Schizophrenia: Science and Practice, (ed.) J.C. Shershow, Harvard University Press, Boston, pp. 122-151, 1978.

    15. Creese, I., Burt, D.R. and Snyder, S.H., Biochemical actions of neuroleptic drugs: focus on the dopamine receptor. In Handbook of Psychopharmacology,Section III, Vol. 10, (eds.) L.L. Iversen, S.D. Iversen and S.H. Snyder, Plenum Press, New York, pp. 37-89, 1978.

    16. Creese, I., Drug screening. In Neurotransmitter Receptor Binding, (eds.) H.I. Yamamura, S.J. Enna and M.J. Kuhar, Raven Press, New York, pp. 141-170, 1978.

    17. Creese, I., Receptor binding: a tool to aid in determining the role of peptides in behavior. In Peptides and Behavior, Neurosciences Research Program Bulletin, Vol. 1 No. 46, pp. 498-509, 1978.

    18. Snyder, S.H. and Creese, I., Chronic neuroleptic treatment and dopamine receptor binding, its relevance to tardive dyskinesia. In Tardive Dyskinesia: Research and Treatment, (eds.) W.E. Fahn, R.C. Smith, J.M. Davis and E.F. Domino, Spectrum Books, New York, pp. 127-137, 1979.

    19. Creese, I., Childers, S.R., Simantov, R. and Snyder, S.H., Differential binding properties of some opiates and opioid peptides. In Endorphins in Mental Health Research, (eds.) E. Usdin, W. Bunney and N. Kline, MacMillan Press, London, pp. 366-377, 1979.

    20. Creese, I. and Snyder, S.H., Multiple dopamine receptors. Catecholamines: Basic and Clinical Frontiers, (eds.) E. Usdin, I. Kopin and J.Barchas, Pergamon Press, pp. 601-603, 1979.

    21. Snyder, S.H., Childers, S.R. and Creese, I., Molecular actions of opiates: historical overview and new findings on opiate receptor interactions with enkephalins and guanyl nucleotides. In Neurochemical Mechanisms for Opiate and Endorphin Actions (Adv. Biochem. Psychopharmacol.) Vol. 20 (eds.) H.H. Loh and D.H. Ross, Raven Press, New York, pp. 543-552, 1979.

    22. Snyder, S.H., U'Prichard and Creese, I., Catecholamine receptor binding in brain. In Catecholamines: Basic and Clinical Frontiers, (eds.) E. Usdin, I. Kopin and J. Barchas, Pergamon Press, pp. 535-541, 1979.

    23. Creese, I. and Snyder, S.H., Chronic neuroleptic treatment and dopamine receptor regulation. In Long Term Effects of Neuroleptics, (eds.) F. Cattabeni, G. Racagni, P.F. Spano and E. Costa, Raven Press, pp. 89- 94, 1980.

    24. Creese, I., Proceedings Editor: Multiple Dopamine Receptors, Communications in Psychopharmacology, 3: 383-384, 1979.

    25. Creese, I., Receptors for psychoactive drugs in the central nervous system. In Cell Surface Reviews,Vol. 6 The Cell Surface and Neuronal Recognition, (eds.) C.W. Cotman, G. Poste and G.L. Nicholson, Elsevier/North-Holland Publishing Co., New York, pp. 261-301, 1980.

    26. Mackay, A.V.P., Bird, E.D., Iversen, L.L., Spokes, E.G., Creese, I. and Snyder, S.H., Dopaminergic abnormalities in postmortem brain. In Long Term Effects of Neuroleptics, (eds.) F. Cattabeni, G. Racagni, P.F. Spano and E. Costa, Raven Press, New York, pp. 325-333, 1980.

    27. Creese, I., Central nervous system dopamine receptors. In Receptors for Neurotransmitters and Peptide Hormones, (eds.) G. Pepeu, M.J. Kuhar and S.J. Enna, Raven Press, pp. 235-242, 1980.

    28. Creese, I. and Sibley, D.R., Regulation of dopamine receptors. In Psychopharmacology and Biochemistry of Neurotransmitter Receptors. (eds.) H.I. Yamamura, R.W. Olsen and E. Usdin, Raven Press, New York, pp. 387-410, 1980.

    29. Creese, I., Dopamine receptors. In Neurotransmitter Receptors, Part 2: Biogenic Amines (eds.) H.I. Yamamura and S.J. Enna, Chapman & Hall Ltd, London, pp. 129-183, 1981.

    30. Creese, I., Lader, S., and Rosenberg, B., A radioreceptor assay for neuroleptic drugs. In Clinical Pharmacology in Psychiatry: Neuroleptic and Antidepressant Research, (eds.) E. Usdin, S.G. Dahl, L.F. Gram and O. Lingjaerde, Macmillan Press, pp. 79-104, 1981.

    31. Creese, I., Morrow, A.L., Leff, S.E., Sibley, D.R. and Hamblin, W. Dopamine receptors in the central nervous system. International Review of Neurobiology, Vol 23 (eds.) J.R. Smythies and R.J. Bradley, Academic Press, pp. 255-301, 1982.

    32. Creese, I., Hamblin, M.W., Leff, S.E. and Sibley, D.R., CNS dopamine receptors. In Psychobiology of Schizophrenia (eds.) M. Namba and H. Kaiya, Pergamon Press, Oxford, pp. 139-153, 1982.

    33. Creese, I., Sibley, D.R., Hamblin, M.W. and Leff, S.E., Dopamine receptors in the central nervous system. In Molecular Pharmacology of Neurotransmitter Receptors Advances in Biochemical Psychopharmacology Vol. 36 (eds.) T. Segawa, H. Yamamura, K. Kuriyama, Raven Press, pp. 125-134, 1983.

    34. Creese, I., Hamblin, M.W., Leff, S.E. and Sibley, D.R., CNS dopamine receptors. In Handbook of Psychopharmacology, Vol. 17, (eds.) L.L. Iversen, S.D. Iversen and S.H. Snyder, Plenum Publishing Corp., pp. 81-138, 1983.

    35. Creese, I., Receptor interactions of neuroleptics. In Neuroleptics (eds.) J.T. Coyle and S.J. Enna, Raven Press, New York, pp. 183-222, 1983.

    36. Loy, R., Morrow, A.L. and Creese, I., Cholinergic denervation induces adrenergic receptor increases: correlation with sympathetic axon sprouting in hippocampus. In Nervous System Regeneration, Vol. 19 (eds.) B. Haber, R. Perez-Polo, G.A. Hashim and A.M.G. Stella, A.R. Liss, Inc., pp. 409-415, 1983.

    37. Creese, I., Sibley, D.R. and Leff, S.E., Classification of dopamine receptors. In CNS Receptors--From Molecular Pharmacology to Behavior (eds.) P. Mandel and F.V. Defeudis, Raven Press, pp. 255-266, 1983.

    38. Creese, I., Morrow, A.L., Leff, S.E., Hamblin, M.W. and Sibley, D.R., Radioligand binding studies of CNS dopamine receptors. In Receptors as Supramolecular Entities, Proceedings onf the 2nd Capo Boi Symposium of Neuroscience (eds.) G. Biggio, P. Spano and G. Gessa, Per- gamon Press, pp. 1-50, 1983.

    39. Creese, I., Multiple dopamine receptors--their role in schizophrenia. The Brain, Biochemistry, and Behavior Proceedings of the 6th Arnold O.Beckman Conference in Clinical Chemistry., (ed.) R.L. Habig, American Association for Clinical Chemistry Inc., pp. 243-290, 1984.

    40. Leff, S.E. and Creese, I. Dopamine receptors reexplained. In Receptors Again (ed.) J.W. Lamble, Elsevier/N. Holland, pp. 119-127, 1984.

    41. Leff, S.E. and Creese, I., Neuroleptic binding sites in brain. In Brain Receptor Methodologies, Part B. (eds.) P.J. Marangos, I. Campbell and R.M. Cohen, Academic Press, New York, pp. 249-277, 1984.

    42. Creese, I., Leff, S.E., Sibley, D.R. and Hamblin, M.W., Radioligand binding studies of agonist interactions with dopamine receptors. Dopamine Agonists (eds.) A. Poste and S.T. Crooke Plenum Press, pp. 23- 64, 1984.

    43. Creese, I., Receptor binding as a primary drug screen. In Neurotransmitter Receptor Binding, Second Edition (eds.) H.I. Yamamura, S.J. Enna and M.J. Kuhar, Raven Press, New York, pp. 189-233, 1984.

    44. Creese, I., Gariano, R. and Leff, S.E., Dopamine receptor turnover rates in rat striatum are age-dependent. In Clinical Neuropharmacology Vol. 7 (eds.) A. Racagni, R. Paoletti and P. Kielholz) Raven Press, New York, pp. 790-791, 1984.

    45. Creese, I., Binding interactions of neuroleptic drugs with dopamine receptors and their implications. In Behavioral Pharmacology: The Current Status (eds.) L.S. Seiden and R.L. Balster, A.R. Liss, Inc., New York, pp. 221-241, 1985.

    46. Creese, I., Dopamine and antipsychotic medications. In Psychiatry Update ,Vol. IV (eds.) R.E. Hales, and A.J. Frances, American Psychiatric Press, Inc., Washington, D.C., 17-36, 1985.

    47. Creese, I., Dopamine receptors explained. In Neurotransmitters in Action (ed.) D. Bousfield, Elsevier/N. Holland. pp. 242-251, 1985.

    48. Creese, I., Receptors, radioligand binding, and psychiatric disorders. In Psychiatry (eds.) R. Michels, J.O. Cavenar, H.K.H. Brodie, A.M. Cooper, S.B. Guze, L.L. Judd, G.L. Klerman, A.J. Solnit. J.B. Lippincott Co., Philadelphia, PA, Vol. 3, Section 50: 1-16, 1985.

    49. Creese, I. , Dopamine receptor subtypes. Centerfold in Trends in Pharmacological Sciences , Elsevier Press, Cambridge, October, 1985.

    50. Creese, I. and Hess, E.J., Neuroleptic receptor binding in drug research. In Receptor Binding in Drug Research (ed.) R. O'Brien, Marcel Dekker, Inc., New York, 123-149, 1986.

    51. Creese, I. and Leff, S.E., Regulation of agonist interactions with D1 dopamine receptors. In Dopaminergic Systems and Their Regulation (eds.) G. Woodruff, J. Poat and P. Roberts, MacMillan Press, 79-95, 1986.

    52. Creese, I., Dopamine receptors. In The Receptors (ed.) P.M. Conn, Academic Press, New York, 171-212, 1986

    53. Hess, E.J. and Creese, I., Biochemical and behavioral studies of D1 dopamine receptors utilizing SCH23390. In Neurobiology of Central D1 Dopamine Receptors (eds.) G. Breese and I. Creese, Plenum Press, N.Y., 29-52, 1986.

    54. Hess, E.J. and Creese, I., Biochemical characterization of dopamine receptor subtypes. In Structure and Function of Dopamine Receptors (eds.) I. Creese and C. Fraser, A.R. Liss, N.Y., 1-27, 1987.

    55. Creese, I., Dopamine receptors. In Encyclopedia of Neuroscience (ed.) G. Adelman, Birkhauser Boston, Inc., Massachusetts, 333-334, 1987.

    56. Creese, I., Biochemical properties of CNS dopamine receptors. In Psychopharmacology - The Third Generation of Progress (ed.) H.Meltzer, American College of Neuropsychopharmacology, and Raven Press, New York, 257-264, 1987.

    57. Creese, I., Multiple dopamine receptors. In Perspectives in Psychopharmacology, Neurology and Neurobiology Vol. 40 (eds.), J. Barchas and W. Bunney, A.R. Liss, Inc., New York, 195-206, 1987.

    58. Creese, I., Dopamine receptor subtypes: differential regulatory characteristics and levels in schizophrenia. In Dopamine Systems and their Regulation (eds.) P.M. Beart, G.N. Woodruff, and D.M. Jackson, Macmillan Press, New York, 364-370, 1988.

    59 . Creese, I. , New insights into the regulation of dopamine receptor subtypes and their roles in behavior. In Progress in Parkinson Research. (eds.) Franz F. Hefti and William J. Weiner, Plenum Press, NewYork, 45-51, 1988.

    60. Creese, I. Dopamine Receptor Subtypes: Differential regulatory characteristics and role in schizophrenia. In Molecular Neurobiology: First NIMH Conference on Molecular Neurobiology, (eds.) S. Zalcman and R. Scheller, U.S. Dept. of Health and Human Services, NIMH, Rockville, M.D., 272, 1988.

    61. Riva, M. and Creese, I. Lack of serotonergic influence on desipramine-induced b-adrenergic receptor down-regulation. In Serotonin: From Cell Biology to Pharmacology and Therapeutics (eds.) R. Paoletti, P. M. Vanhoutte, N. Brunello and F. M. Maggi., Kluwer Academic Publishers, 481-485, 1990.

    62. Creese, I. Dopamine Receptors: Regulation and role in schizophrenia. In Fudan Lectures in Neurobiology, The School of Life Sciences, Fudan University, Shanghai, China, VI:9-26, 1990.

    63. Creese, I. Problems in Analyzing Radioligand Binding: Focus on b-adrenergic receptors and antidepressant mechanisms. In Fudan Lectures in Neurobiology, The School of Life Sciences, Fudan University, Shanghai, China, VI:27-34, 1990.

    64. Creese, I. and Xu, S. Regulation of D2 dopamine receptor mRNA following denervation or chronic haloperidol treatment. In Biological Psychiatry, Vol. 2, Proceedings of 5th World Congress of Biological Psychiatry, (eds.) G. Racagni, N. Brunello and T. Fukuda., Elsevier Press, Amsterdam, The Netherlands, 681-684, 1991.

    65. Tarazi, F.I.; Florijn, W.J.; Creese, I.., Regulation of Dopamine D2-Like Receptor Subtypes Following Chronic Typical or Atypical Neuroelepic Treatment. In Critical Issues in the Treatment of Schizophrenia, (eds.) G. Racagni and N. Brunello, International Academy for Biomedical and Drug Research, 10:102-105,1995.

    66. Zhang,M., Ouagazzal, A. and Creese, I., Regulation of motor behavior by dopamine receptor subtypes: an antisense knockout approach. In The Dopamine Receptors, (eds.) K. Neve and R. Neve, Humana Press, Totawa, New Jersey, 14:425-455, 1996.

    67. Zhang, M., Sun, B.C., Martin, L.P., Tepper, J.M. and Creese, I., Antisense strategies for determining CNS dopamine receptor function. InPerspectives in Neuroscience Research (eds) C.K. Tan and E.A. Ling, 1-11, 1996.

    68. Creese, I., Zhang, M., Sun, B. C., Ouagazzal, A., Martin, L.P., and Tepper, J. M., Dopamine receptor function: an analysis utilizing antisense knockout in vivo. In Pharmacological Regulation of Gene Expression in the CNS, (ed.) K. M. Merchant, CRC Press, 51-78, 1996.

    69. Tepper, J.M., Sun, B.-C., Martin, L.P., and Creese, I., Electrophysiological correlates of in vivo antisense knockout of dopamine D2 autoreceptors on substantia nigra dopaminergic neurons (DSG). In Antisense Strategies for the Study of Receptor Mechanisms (eds.) R. B. Raffa and F. Porreca, R. G. Landes Company, Austin, 93-110, 1996.

    70. Tepper, J.M., Sun, B.-C., Martin, L.P., and Creese, I., Electrophysiological consequences of D2 and/or D3 receptor knockout by antisense oligodeoxynucleotides in nigrostriatal dopaminergic neurons. In The Basal Ganglia V. (eds.) C. Ohye, M. Kimura and J. McKenzie, Plenum Press, New York, 16:141-149, 1996.

    71. Ouagazzal, A., Tepper, J.M. and Creese, I., Reducing gene expression in the brain via antisense methods. Basic Protocol: Antisense oligodeoxynucleotides to reduce expression of target p`rotein in the brain. In Current Protocols in Neuroscience , (ed.) V. Chanda, John Wiley and Sons, New York, 5.4.1-5.4.15 (Molecular Neuroscience), 1997.

    72. Creese, I., Burt, D.R. and Snyder, S.H., Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs. "Neuropsychiatry Classics" In Journal of Neuropsychiatry, 8:(2)223-226, 1996.

    73. Florijn, W., Tarazi, F. and Creese, I., Dopamine Receptors. In Principles of Medical Biology, (eds.) E.E. Bittar and N. Bittar., JAI Press, Vol. 8A, Chap. 4, 73-94, 1997.

    74. Ouagazzal, A., Tepper, J.M. and Creese, I., Antisense Oligodeoxynucleotide Technology: Application to CNS Neuropharmacology. In Neuromethods: In Vivo Neuromethods (eds.) A.A. Boulton and G.B. Baker, Humana Press, Totowa, New Jersey, 32:295-324, 1998.

    75. Creese, I. and Tepper, J.M. , Antisense Knockdown of Brain Dopamine Receptors. In Advances in Pharmacology (eds.) D. Goldstein, G. Eisenhofer and R. McCarty, Academic Press, San Diego, 42:517-520, 1998.

    76. Kaur, S., Creese, I. and Tepper, J.M., Electrophysiological and Behavioural Effects of Dopamine Receptor Knockdown in the Brain. In Antisense Technology in the Central Nervous System (eds.) R. Leslie, A.J. Hunter and H. A. Robertson, Oxford University Press, U.K., 6:81-97, 1999.

    77. Kaur, S. and Creese, I., Antisense Knockdown of Dopamine Receptors. In Central Nervous System Diseases (eds.) P. Sanberg, D. F. Emerich and R. L. Dean, Humana Press, Inc. Totowa, New Jersey, 209-226, 1999.

    78. Taylor, L. and Creese, I. Regulation of Neurotransmitter Receptors by Antipyschotic Drugs. In Neurotransmitter Receptors in Actions of Antipsychotic Medications (ed.) M.S. Lidow, CRC Press, 12:177-198, 2000.

    79. Kaur, S., Creese, I., Delivery of Antisense Oligonucleotides to the Brain to Analyze Receptor Function. In Genetic Manipulation of Receptor Expression and Function (ed.) D. Accili, Wiley-Liss, Inc., 12:205-222, 2000.

    80. Taylor, L. and Creese, I., Dopamine. In Encyclopedia of the Human Brain (ed.) V.S. Ramachandran, Academic Press, Vol 2 p115-122, 2002.

  • Research Initiatives

     

     

     

  • Expertise

    Research Interest: Neuropsychopharmacology